The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
Natalizumab, a monoclonal antibody that blocks lymphocyte infiltration in the central nervous system, is a valuable tool in the treatment of relapsing forms of multiple sclerosis (MS). In a phase III clinical trial comparing natalizumab with placebo over 2 years, natalizumab reduced annualized relap...
Main Author: | Barry A. Singer |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-09-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756285617716002 |
Similar Items
-
Natalizumab in the treatment of multiple sclerosis
by: Brandon A Brown
Published: (2009-07-01) -
Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis
by: J. Theodore Phillips, et al.
Published: (2008-11-01) -
Natalizumab treatment for multiple sclerosis
by: Maria Lucia Brito Ferreira
Published: (2014-12-01) -
Natalizumab for the treatment of relapsing multiple sclerosis
by: Richard A Rudick, et al.
Published: (2008-06-01) -
Risk acceptance in multiple sclerosis patients on natalizumab treatment.
by: Carmen Tur, et al.
Published: (2013-01-01)